Joanne L Billings – Projects and Grants — Experts@Minnesota

View Scopus Profile

Emailbilli001umnedu

Research activity per year

If you made any changes in Pure these will be visible here soon.

12 Active
54 Finished

1 - 50 out of 66 results

Active

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
Blazar, B. R., Beebe, T. J., Bellin, M. D., Berge, J. M., Billings, J. L., Bischof, J. C., Brearley, A. M., Call, K. T., Fu, S. S., Fulkerson, J., Guan, W., Hardeman, R. R., Haynes, D. A., Henning-Smith, C. E., Johnson, S., Jones-Webb, R. J., Kozhimannil, K. B., Langworthy, B., Lim, H. H., Melton-Meaux, G. B., Nunez, A., Pakhomov, S. V., Pieczkiewicz, D. S., Randolph, A. C., Riggs, S., Rudser, K., Schleiss, M. R., Shen, S., Vaughn, B. P. & Vock, D. M.
NIH NAT'L CTR FOR ADVANCING TRAN SCIENCE
9/18/23 → 7/31/30
Project: Research project
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF (STRONG-CF)
Billings, J. L.
JAEB CENTER FOR HEALTH RESEARCH, CYSTIC FIBROSIS FOUNDATION
6/22/23 → 1/31/25
Project: Research project
Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF)
Billings, J. L.
UNIVERSITY OF PITTSBURGH, NATIONAL INSTITUTES OF HEALTH (NIH)
2/1/23 → 1/31/24
Project: Research project
A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability ofVX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTRGenotype Not Responsive to CFTR Modulator Therapy
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
10/1/22 → 10/1/24
Project: Research project
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
8/1/22 → 8/1/25
Project: Research project
Cystic Fibrosis Foundation Therapeutic, Inc. Therapeutics Development Center Award
Billings, J. L. & Goldfarb, S.
CYSTIC FIBROSIS FOUNDATION
4/1/22 → 3/31/24
Project: Research project
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacyand Safety of VX-121Combination Therapy in Subjects With Cystic FibrosisWho Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
9/1/21 → 6/30/24
Project: Research project
MAYFLOWERS-0B-20: A Prospective Study Evaluating Maternal and FetaL Outcomes in the ERa of ModulatorS (MAYFLOWERS)
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
4/1/21 → 4/1/25
Project: Research project
Optimal vancomycin exposure target for pulmonary exacerbations in CF
Illamola, S. M., Billings, J. L., Evans, M. D. & Hirsch, E. B.
CYSTIC FIBROSIS FOUNDATION
1/1/21 → 12/31/23
Project: Research project
Antibacterial Resistance Leadership Group (ARLG)
Billings, J. L.
DUKE UNIVERSITY, NATIONAL INSTITUTES OF HEALTH (NIH)
12/1/20 → 11/30/26
Project: Research project
PROMISE-OB-18, A prospective study to evaluate biological and clinical effects of significantly correctedCFTR function (the PROMISE Study) (Pro00029275)
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
11/1/18 → 7/31/25
Project: Research project
CHEC-OB-17 CHaractErizing CFTR Modulated Changes in
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
7/1/17 → 12/31/24
Project: Research project
Finished

Collaborative Cohort of Cohorts for COVID-19 Research (C4R)
Billings, J. L.
NATIONAL JEWISH HEALTH, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU
3/3/21 → 12/31/22
Project: Research project
SIMPLIFY-IP-19: A protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
1/1/20 → 12/31/22
Project: Research project
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
7/30/19 → 12/31/22
Project: Research project
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
7/30/19 → 12/31/22
Project: Research project
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Olderwith Cystic Fibrosis
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
6/1/19 → 7/31/22
Project: Research project
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
5/23/19 → 1/1/21
Project: Research project
Sexual and Reproductive Health in Adult Women with Cystic Fibrosis
Billings, J. L.
UNIVERSITY OF PITTSBURGH, CYSTIC FIBROSIS FOUNDATION
4/1/19 → 3/31/20
Project: Research project
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacyof VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
3/21/19 → 1/1/21
Project: Research project
APPLAUD: A double-blinded, randomized, placebo-controlled, Phase 2 study of the efficacy and safety ofLAU-7B in the treatment of cystic fibrosis through correction of the AA/DHA imbalance
Billings, J. L.
LAURENT PHARMACEUTICALS INC
11/1/18 → 10/31/21
Project: Research project
PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 inSubjects with Cystic Fibrosis
Billings, J. L.
PROTEOSTASIS THERAPEUTICS, INC.
9/28/18 → 1/1/20
Project: Research project
PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 inHealthy Adult Subjects and in Adults with Cystic Fibrosis
Billings, J. L.
PROTEOSTASIS THERAPEUTICS, INC.
7/1/18 → 1/1/21
Project: Research project
VX17-659-105: A Phase 3, Open-label Study Evaluating the
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
5/9/18 → 5/1/21
Project: Research project
VX17-659-102: A Phase 3, Randomized, Double-blind, Contr
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
4/12/18 → 3/12/20
Project: Research project
VX16-809-120: A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety ofOrkambi in US Patients Who Completed Study VX12-809-105 Part A
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
4/1/18 → 12/31/19
Project: Research project
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
Blazar, B. R., AbuSalah, A. M., Adam, T. J., Aliferis, MD, PhD, C., Allen, J., Beckman, K. B., Billings, J. L., Bloomfield, H. E., Bornsztein, B., Brearley, A. M., Call, K. T., Chi, C., Clancy, T. R., Connett, J. E., Daniels, B. S., Eder, M., El-Fakahany, E. E., Fischer, G., Fulkerson, J., Garwood, M., Georgopoulos, A. P., Guan, W., Henderson, J. N., Hodges, J. S., Ingbar, D. H., Jones-Webb, R. J., Jordan, C., Karypis, G., Knights, D., Kumar, V., LeBien, T. W., Lim, K. O., Ma, S., Melton-Meaux, G. B., Myers, C. L., Neuhauser, C., Oakes, M., Okuyemi, K., Pakhomov, S. V., Panoskaltsis-Mortari, A., Pieczkiewicz, D. S., Raymond, N. C., Riggs, S., Rudser, K., Ruggles, S., Schacker, T. W., Schleiss, M. R., Shekhar, S., Shen, S., Simon, G. J., Ugurbil, K., Vock, D. M., Volkov, B. B., Wang, J., Warren, R., Weber-Main, A. M., Weisdorf, D. J., Wolf, S. M., Zellmer-Bruhn, M. E. & Zhang, R.
NIH NAT'L CTR FOR ADVANCING TRAN SCIENCE
3/30/18 → 11/17/23
Project: Research project
Novartis CQBW276X2201: A randomized, double blind, place
Billings, J. L.
NOVARTIS PHARMACEUTICALS CORPORATION
6/1/17 → 1/11/20
Project: Research project
VX15-440-101: A Phase 2, Randomized, Double-blind, Contr
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
11/6/16 → 1/1/20
Project: Research project
GS-US-404-1808: A Phase 2b, Dose-Ranging Study of the Ef
Billings, J. L.
GILEAD SCIENCES, INC.
11/1/16 → 11/1/20
Project: Research project
Nurse Practitioner Additional Research Coordinator(ARC)
Billings, J. L.
CYSTIC FIBROSIS FOUNDATION
1/1/16 → 3/31/23
Project: Research project
VX15-371-101: A Phase 2a, Randomized, Double-blind
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
12/15/15 → 5/31/18
Project: Research project
Multicenter Clinical Phenotyping of Cystic Fibrosis
Billings, J. L.
UNIVERSITY OF CALIFORNIA SAN DIEGO, GILEAD SCIENCES, INC.
12/1/15 → 11/13/17
Project: Research project
VX14-661-110: A Phase 3, Open-label, Rollover Study to E
Billings, J. L. & Laguna, T.
VERTEX PHARMACEUTICALS INCORPORATED
10/5/15 → 10/5/18
Project: Research project
N91115-2CF-05 (SNO-6): A Phase 2, Randomized, Double-Bli
Billings, J. L.
NIVALIS THERAPEUTICS, INC.
9/15/15 → 12/31/16
Project: Research project
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124)
Billings, J. L.
PTC THERAPEUTICS, INC.
3/20/15 → 3/20/16
Project: Research project
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled
Billings, J. L.
NIVALIS THERAPEUTICS, INC.
1/31/15 → 1/31/17
Project: Research project
2015 Therapeutics Development Center Spring Meeting
Billings, J. L.
CYSTIC FIBROSIS FOUNDATION
1/1/15 → 6/30/15
Project: Research project
University of Minnesota Additional Research Coordinator
Billings, J. L.
CYSTIC FIBROSIS FOUNDATION
1/1/15 → 3/31/22
Project: Research project
DMP-CF-303: Long Term Administration of Inhaled Mannitol
Billings, J. L.
PHARMAXIS LTD
10/1/14 → 10/1/17
Project: Research project
A Two-Part Multicenter Prospective Longitudinal Study
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
7/1/14 → 1/31/19
Project: Research project
VX12-809-105: A Phase 3, Rollover Study to Evaluate
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
12/6/13 → 12/6/16
Project: Research project
The EPIC Observational Study: Longitudinal Assessment of
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, CYSTIC FIBROSIS FOUNDATION
9/1/13 → 10/1/20
Project: Research project
A Phase 2, Multi-Center, Randomized, Placebo-Controlled
Billings, J. L.
SEATTLE CHILDREN'S HOSPITAL, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU
9/1/13 → 6/30/18
Project: Research project
A Phase 3, Randomized, Double Blind, Placebo Controlled,
Billings, J. L.
VERTEX PHARMACEUTICALS INCORPORATED
1/31/13 → 1/31/16
Project: Research project
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled
Billings, J. L.
NIVALIS THERAPEUTICS, INC.
1/15/13 → 1/15/15
Project: Research project
Genetic Epidemiology of COPD
Billings, J. L.
NATIONAL JEWISH HEALTH, NIH NAT'L HEART, LUNG, AND BLOOD INSTITU
1/1/13 → 7/31/23
Project: Research project
KB001A-05, A Phase 2, Randomized, Double-blind, Placebo-
Billings, J. L.
KaloBios Pharmaceuticals, Inc.
11/30/12 → 6/30/15
Project: Research project
A Long-Term Prospective Observational Study of the Incid
Billings, J. L.
CYSTIC FIBROSIS FOUNDATION, ABBOTT LABORATORIES
6/1/12 → 6/1/23
Project: Research project
Prospective Observational Study to Evaluate Biomarkers
Billings, J. L. & Dunitz, J. M.
FOUNDATION FOR THE NAT'L INST. OF HEALTH
4/1/12 → 6/30/16
Project: Research project